TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
The Intellia Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $18.81 and its highest was $202.73 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $11.41B.
What is Intellia Therapeutics’s price target?
The average price target for Intellia Therapeutics is $174.94. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $252.00 ,the lowest forecast is $130.00. The average price target represents 12.68% Increase from the current price of $155.26.
What do analysts say about Intellia Therapeutics?
Intellia Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Nov 02, 2021 which is next month.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Aug 05, 2021. The company reported -$1.009 earnings per share for the quarter, missing the consensus estimate of -$0.634 by -$0.375.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 73,490,000 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$1.009 in its last earnings report, missing expectations of -$0.634. Following the earnings report the stock price went up 13.863%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Among the largest hedge funds holding Intellia Therapeutics’s share is ARK Investment Management LLC. It holds Intellia Therapeutics’s shares valued at 1B.